SCHEMBL26315817

SCHEMBL26315817

Cc1ccc2c(c1)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCOCCOCCN)c1nnc(C)n1-2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 16/20 0.68
▸ BRD2 P25440 5/20 0.68
▸ BRD3 Q15059 5/20 0.68
▸ HDAC1 Q13547 3/20 0.63
▸ HDAC2 Q92769 3/20 0.63
▸ SMCHD1 A6NHR9 1/20 0.63
▸ MYO1G B0I1T2 1/20 0.63
▸ AIP O00170 1/20 0.63
▸ AP3B1 O00203 1/20 0.63
▸ PSMD11 O00231 1/20 0.63
▸ CDC7 O00311 1/20 0.63
▸ SAP18 O00422 1/20 0.63
▸ KPNA3 O00505 1/20 0.63
▸ PPP6C O00743 1/20 0.63
▸ TCERG1 O14776 1/20 0.63
▸ UBE2L6 O14933 1/20 0.63
▸ PPP1R12A O14974 1/20 0.63
▸ U2SURP O15042 1/20 0.63
▸ SETD1A O15047 1/20 0.63
▸ ARPC1B O15143 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26258766 1.00 BRD4 (0.68) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL15969457 0.92 BRD4 (0.76) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL15967908 0.92 BRD4 (0.76) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL15970363 0.92 BRD4 (0.76) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL15969702 0.92 BRD4 (0.76) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL16758307 0.92 BRD4 (0.76) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL15969510 0.92 BRD4 (0.76) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL26258737 0.91 BRD4 (0.67) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL26258767 0.90 BRD4 (0.69) BRD4BRD2BRD3HDAC1HDAC2
SCHEMBL26315814 0.90 BRD4 (0.69) BRD4BRD2BRD3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE CORNELL UNIVERSITY 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277553-A1 THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE BET1, BRD4, PHKB BRD4 2/4885BRD2 12/4885BRD3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback